What is the Difference Between Convalescent Plasma and Monoclonal Antibodies?

Convalescent plasma and monoclonal antibodies are both antibody-based therapies used to treat COVID-19, but they differ in their production and composition.

Convalescent Plasma:

Derived from people who have recovered from COVID-19 and donated their plasma.
Contains a mixture of various antibodies, including those that target the virus.
The antibody content in convalescent plasma may vary depending on the donor and the specific sample.
Studies have shown that early treatment with convalescent plasma can reduce mortality in high-risk patients.

Monoclonal Antibodies:

Manufactured in a laboratory.
Target a specific antigen, which is a protein or molecule associated with the virus.
Contain a single, cloned antibody that is designed to bind to a specific antigen.
Monoclonal antibodies with high antibody content have been shown to improve patient outcomes.

In summary, convalescent plasma is derived from the plasma of recovered COVID-19 patients, while monoclonal antibodies are laboratory-produced antibodies that target specific antigens. Both therapies have shown potential in treating COVID-19, but their effectiveness may vary depending on factors such as the timing of administration and the specific antibody content.

On this page

What is the Difference Between Convalescent Plasma and Monoclonal Antibodies?

Comparative Table: Convalescent Plasma vs Monoclonal Antibodies

Here is a table highlighting the differences between convalescent plasma and monoclonal antibodies:

Characteristic	Convalescent Plasma	Monoclonal Antibodies
Definition	Convalescent plasma therapy is a type of treatment in which the blood plasma of one person who has recovered from an infection is used to treat another individual with the same infection.	Monoclonal antibodies are proteins made in a laboratory to treat specific infections.
Formation	Convalescent plasma is made in the person's body and then extracted and put through plasmapheresis.	Monoclonal antibodies are made in a laboratory by first injecting antigens into a mouse and then synthesizing and cloning them.
Variability	Convalescent plasma varies because immune system responses vary.	Monoclonal antibodies do not vary as they are synthesized and cloned in the laboratory.
Advantages	An advantage of convalescent plasma therapy is that it works well for many viruses and is inexpensive.	Examples: Covid-19 plasma has been taken from patients who have been ill and recovered, and used to treat severely ill Covid-19 patients.
Disadvantages	Although rare, there are some potential dangers associated with convalescent plasma therapy, such as allergic responses and lung damage.

Both convalescent plasma and monoclonal antibodies are antibody-based therapies, but they differ in how they are made and their variability.

Guilherme Mazui

Guilherme Mazui is graduated in journalism from the Federal University of Minas Gerais (UFMG) and a master's degree in Communication from the University of São Paulo (USP). In addition, he has experience in advertising writing and has worked as a content editor in several companies.